single10MG
Semaglutide
10MG Protocol
Semaglutide 10MG
Injection Freq.
Inject once weekly
Cycle Sched.
Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation
Reconstitution
3.0 mL BAC water
Significant weight loss (~10–15% mean in trials with lifestyle support)
Improved glycemic control via glucose-dependent insulin secretion
Reduced appetite and food intake via CNS GLP-1 signaling
Cardiovascular outcome benefits reported (reduced MACE risk)
Once-weekly dosing convenience
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–4 | 250 mcg (0.25 mg) | 7.5 |
| 2 | Weeks 5–8 | 500 mcg (0.5 mg) | 15 |
| 3 | Weeks 9–12 | 1000 mcg (1.0 mg) | 30 |
| 4 | Weeks 13–16 | 1700 mcg (1.7 mg) | 51 |
| 5 | Weeks 1+ | 2400 mcg (2.4 mg) | 72 |
Inject once weekly
Weekly subcutaneous injections for 16–20+ weeks with gradual dose escalation
The Semaglutide (semaglutide) 10 mg protocol describes a GLP-1 receptor agonist that is engineered for long duration so it can be dosed weekly. Mechanistically, the page explains three major effects: (1) appetite suppression and reduced food intake through central GLP-1 signaling; (2) slowed gastric emptying, which lowers meal-related glucose spikes; and (3) improved glycemic control through glucose-dependent insulin secretion with reduced glucagon output. The protocol notes that the extended half-life (~7 days) results from albumin binding and resistance to enzymatic degradation by DPP-4. Clinical outcomes summarized include meaningful weight loss (often reported in the 10–15% range with lifestyle support) and improved glucose control, with cardiovascular outcome benefits also described. The main tolerability limitation presented is gastrointestinal side effects that are dose-dependent and typically improved through gradual titration.
Nausea, vomiting, diarrhea, constipation, abdominal pain
Injection-site reactions (redness/swelling/irritation)
Hypoglycemia risk when combined with insulin/sulfonylureas
Rare: pancreatitis, gallbladder disease, acute kidney injury
Thyroid C-cell tumors seen in rodents (human relevance uncertain)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)